AVEO Pharmaceuticals Investor Relations Material
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in finding, acquiring, developing and commercializing novel cancer therapeutics for patients. The company´s lead anti-cancer candidate, Tivozanib, is an oral pan-targeted receptor tyrosine kinase inhibitor that AVEO believes may offer therapeutic benefits to adult patients with various types of cancer, including kidney cancer, breast cancer and colon cancer. The company is also developing a biomarker that could enable physicians to identify earlier in treatment those patients who respond favorably or unfavorably to therapy with Tivozanib or other angiogenesis inhibitors.
Edward "Ted" Decker's Rise to the Top at Home Depot
Explore Ted Decker's transformative impact on Home Depot, including his leadership in retail innovation and strategic vision alongside Craig Menear.
15 Feb 2024
Andy Jassy: Amazon CEO & Pioneer of Cloud Computing
Discover Andy Jassy's remarkable achievements at Amazon, including the creation of Amazon Web Services and his experiences working with Jeff Bezos.
15 Feb 2024
Stripe’s Rumored 2024 IPO
Anticipation grows around Stripe's rumored 2024 IPO, spotlighting its significant influence in the digital payments sector.
9 Feb 2024
🇺🇸 United States